%0 Journal Article
%T Quantitative Appraisal of Ventricular Cerebrospinal Fluid Biomarkers in Neuropathologically Diagnosed Parkinson's Disease Cases Lacking Alzheimer's Disease Pathology
%A Chera L. Maarouf
%A Thomas G. Beach
%A Charles H. Adler
%A Michael Malek-Ahmadi
%A Tyler A. Kokjohn
%A Brittany N. Dugger
%A Douglas G. Walker
%A Holly A. Shill
%A Sandra A. Jacobson
%A Marwan N. Sabbagh
%A Alex E. Roher and Arizona Parkinson¡¯s Disease Consortium
%J Biomarker Insights
%D 2012
%I 
%R 10.4137/BMI.S11422
%X Identifying biomarkers that distinguish Parkinson¡¯s disease (PD) from normal control (NC) individuals has the potential to increase diagnostic sensitivity for the detection of early-stage PD. A previous proteomic study identified potential biomarkers in postmortem ventricular cerebrospinal fluid (V-CSF) from neuropathologically diagnosed PD subjects lacking Alzheimer¡¯s disease (AD) neuropathology. In the present study, we assessed these biomarkers as well as p-tau181, A¦Â42, and S100B by ELISA in PD (n = 43) and NC (n = 49) cases. The p-tau181/A 42 ratio and ApoA-1 showed statistically significant differences between groups. Multiple regression analysis demonstrated that p-tau181/A¦Â42 had a significant odds ratio: OR = 1.42 (95% confidence interval [CI], 1.12¨C1.84), P = 0.006. Among the molecules investigated, intriguing correlations were observed that require further investigation. Our results suggest co-existent AD CSF biomarkers within the PD group notwithstanding that it was selected to minimize AD neuropathological lesions.
%U http://www.la-press.com/quantitative-appraisal-of-ventricular-cerebrospinal-fluid-biomarkers-i-article-a3589